{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:24:55Z","timestamp":1793366695329,"version":"4.5.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"DOI":"10.3389\/fnins.2020.00507","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T05:21:33Z","timestamp":1590038493000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Emerging Roles of Dysregulated MicroRNAs in Myasthenia Gravis"],"prefix":"10.3389","volume":"14","author":[{"given":"Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13892","DOI":"10.1523\/JNEUROSCI.1733-14.2014","article-title":"LRP4 is critical for neuromuscular junction maintenance.","volume":"34","author":"Barik","year":"2014","journal-title":"J. Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/14656566.2019.1682548","article-title":"Current pharmacotherapeutic options for myasthenia gravis.","volume":"20","author":"Barnett","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.imbio.2016.06.012","article-title":"A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients.","volume":"221","author":"Barzago","year":"2016","journal-title":"Immunobiology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.3892\/mmr.2019.9845","article-title":"Global pathway view analysis of microRNA clusters in myasthenia gravis.","volume":"19","author":"Bo","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neures.2019.02.003","article-title":"miR-1933-3p is upregulated in skeletal muscles of MuSK+ EAMG mice and affects Impa1 and Mrpl27.","volume":"151","author":"Bogatikov","year":"2019","journal-title":"Neurosci. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1113\/JP273291","article-title":"Molecular recognition at cholinergic synapses: acetylcholine versus choline.","volume":"595","author":"Bruhova","year":"2017","journal-title":"J. Physiol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154898","article-title":"Identification, molecular characterization and functional analysis of interleukin (IL)-2 and IL-2like (IL-2L) cytokines in sea bass (Dicentrarchus labrax L.).","volume":"126","author":"Buonocore","year":"2019","journal-title":"Cytokine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000494802","article-title":"MicroRNA-653 inhibits thymocyte proliferation and induces thymocyte apoptosis in mice with autoimmune myasthenia gravis by downregulating TRIM9.","volume":"26","author":"Cao","year":"2019","journal-title":"Neuroimmunomodulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs.","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/WCO.0b013e328357a829","article-title":"Autoimmune mechanisms in myasthenia gravis.","volume":"25","author":"Cavalcante","year":"2012","journal-title":"Curr. Opin. Neurol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104388","article-title":"MicroRNA signature associated with treatment response in myasthenia gravis: a further step towards precision medicine.","volume":"148","author":"Cavalcante","year":"2019","journal-title":"Pharmacol. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2014.05.037","article-title":"Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population.","volume":"343","author":"Chang","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10875-012-9834-5","article-title":"MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1.","volume":"33","author":"Cheng","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1684\/ecn.2015.0367","article-title":"Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patients.","volume":"26","author":"Chunjie","year":"2015","journal-title":"Eur. Cytokine Netw."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01969","article-title":"Metabolism and autoimmune responses: the microRNA connection.","volume":"10","author":"Colamatteo","year":"2019","journal-title":"Front. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2013.12.013","article-title":"Innate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity.","volume":"52","author":"Cordiglieri","year":"2014","journal-title":"J. Autoimmun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.autrev.2018.01.008","article-title":"Analysis of microRNA expression in the thymus of Myasthenia Gravis patients opens new research avenues.","volume":"17","author":"Cron","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00539","article-title":"Causes and consequences of miR-150-5p dysregulation in myasthenia gravis.","volume":"10","author":"Cron","year":"2019","journal-title":"Front. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/2211536606666170811151503","article-title":"Environment and neurodegenerative diseases: an update on miRNA role.","volume":"6","author":"Ferrante","year":"2017","journal-title":"Microrna"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109409","article-title":"Regulatory roles of the miR-200 family in neurodegenerative diseases.","volume":"119","author":"Fu","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B21","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis.","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies.","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts.","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"B24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis.","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s10072-017-3086-3","article-title":"Secretases-related miRNAs in Alzheimer\u2019s disease: new approach for biomarker discovery.","volume":"38","author":"Hajjari","year":"2017","journal-title":"Neurol. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mus.26694","article-title":"Employment in refractory myasthenia gravis: a myasthenia gravis foundation of America registry analysis.","volume":"60","author":"Harris","year":"2019","journal-title":"Muscle Nerve"},{"key":"B27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151535","article-title":"Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp 70 derived 14-Mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors on peripheral blood T cells, B cells and NKT cells.","volume":"11","author":"Hromadnikova","year":"2016","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.3892\/mmr.2018.8768","article-title":"Treatment of experimental autoimmune myasthenia gravis rats with FTY720 and its effect on Th1\/Th2 cells.","volume":"17","author":"Huang","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000547","article-title":"MuSK myasthenia gravis monoclonal antibodies: valency dictates pathogenicity.","volume":"6","author":"Huijbers","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.intimp.2012.07.003","article-title":"Altered let-7 expression in myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells.","volume":"14","author":"Jiang","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s10072-017-3071-x","article-title":"Circulating pro-angiogenic and anti-angiogenic microRNA expressions in patients with acute ischemic stroke and their association with disease severity.","volume":"38","author":"Jin","year":"2017","journal-title":"Neurol. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: mechanisms of differentiation and function.","volume":"30","author":"Josefowicz","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1242\/dev.150110","article-title":"Neuronal LRP4 regulates synapse formation in the developing CNS.","volume":"144","author":"Karakatsani","year":"2017","journal-title":"Development"},{"key":"B35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/bs.ircmb.2018.05.008","article-title":"T lymphocytes and autoimmunity.","volume":"341","author":"Khan","year":"2018","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat4285","article-title":"The microRNA miR-7a-5p ameliorates ischemic brain damage by repressing alpha-synuclein.","volume":"11","author":"Kim","year":"2018","journal-title":"Sci. Signal."},{"key":"B37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clim.2017.03.003","article-title":"CD4(+) FoxP3(+) T regulatory cell subsets in myasthenia gravis patients.","volume":"179","author":"Kohler","year":"2017","journal-title":"Clin. Immunol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture.","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.4049\/jimmunol.1900530","article-title":"OX40L-JAG1-induced expansion of lineage-stable regulatory T cells involves noncanonical NF-kappaB signaling.","volume":"203","author":"Kumar","year":"2019","journal-title":"J. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.imlet.2016.02.005","article-title":"Altered expression of miR-125a-5p in thymoma-associated myasthenia gravis and its down-regulation of foxp3 expression in Jurkat cells.","volume":"172","author":"Li","year":"2016","journal-title":"Immunol. Lett."},{"key":"B41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jneuroim.2018.03.021","article-title":"miR-548k regulates CXCL13 expression in myasthenia gravis patients with thymic hyperplasia and in Jurkat cells.","volume":"320","author":"Li","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.mce.2015.06.003","article-title":"Roles of miR-196a on gene regulation of neuroendocrine tumor cells.","volume":"412","author":"Li","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201848007","article-title":"MiR-181a regulates CD4(+) T cell activation and differentiation by targeting IL-2 in the pathogenesis of myasthenia gravis.","author":"Liu","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clim.2015.12.009","article-title":"MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10.","volume":"164","author":"Liu","year":"2016","journal-title":"Clin. Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neulet.2013.09.014","article-title":"Altered expression of miR-146a in myasthenia gravis.","volume":"555","author":"Lu","year":"2013","journal-title":"Neurosci. Lett."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/WCO.0000000000000596","article-title":"Myasthenia gravis: from autoantibodies to therapy.","volume":"31","author":"Mantegazza","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.intimp.2018.01.036","article-title":"Interleukin-8 favors pro-inflammatory activity of human monocytes\/macrophages.","volume":"56","author":"Meniailo","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1261\/rna.068692.118","article-title":"Post-transcriptional control of miRNA biogenesis.","volume":"25","author":"Michlewski","year":"2019","journal-title":"RNA"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000450","article-title":"Thymectomy lowers the myasthenia gravis biomarker miR-150-5p.","volume":"5","author":"Molin","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mus.26107","article-title":"Myasthenia gravis with muscle-specific tyrosine kinase antibodies: a narrative review.","volume":"58","author":"Morren","year":"2018","journal-title":"Muscle Nerve"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.rti.0000154075.06324.14","article-title":"Thymic hyperplasia in thyroid cancer patients.","volume":"20","author":"Niendorf","year":"2005","journal-title":"J. Thorac. Imaging"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091927","article-title":"Analysis of serum miRNA profiles of myasthenia gravis patients.","volume":"9","author":"Nogales-Gadea","year":"2014","journal-title":"PLoS One"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.2169\/internalmedicine.0966-18","article-title":"Late-onset myasthenia gravis accompanied by amyotrophic lateral sclerosis with antibodies against the acetylcholine receptor and low-density lipoprotein receptor-related protein 4.","volume":"57","author":"Ohnari","year":"2018","journal-title":"Intern. Med."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193723","article-title":"Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: autoantibody profiles and clinical features.","volume":"13","author":"Park","year":"2018","journal-title":"PLoS One"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3233\/JAD-181078","article-title":"The potential role of dysregulated miRNAs in Alzheimer\u2019s disease pathogenesis and progression.","volume":"67","author":"Patel","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s12015-014-9558-4","article-title":"Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate Th1 and Th17 cells subsets.","volume":"11","author":"Pianta","year":"2015","journal-title":"Stem Cell Rev. Rep."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2174\/1389557519666191018170908","article-title":"Inhibitors of cholinesterases in the pharmacology, the current trends.","author":"Pohanka","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","article-title":"Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients.","volume":"356","author":"Punga","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nyas.13510","article-title":"Circulating microRNAs as potential biomarkers in myasthenia gravis patients.","volume":"1412","author":"Punga","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jneuroim.2016.01.003","article-title":"Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis.","volume":"292","author":"Punga","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/bs.ircmb.2017.04.002","article-title":"MicroRNAs in neurodegenerative diseases.","volume":"334","author":"Quinlan","year":"2017","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jemermed.2017.06.009","article-title":"Myasthenia gravis and crisis: evaluation and management in the emergency department.","volume":"53","author":"Roper","year":"2017","journal-title":"J. Emerg. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2018.10.003","article-title":"Circulating microRNA plasma profile in MuSK+ myasthenia gravis.","volume":"325","author":"Sabre","year":"","journal-title":"J. Neuroimmunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jneuroim.2018.05.003","article-title":"Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis.","volume":"321","author":"Sabre","year":"","journal-title":"J. Neuroimmunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/acn3.692","article-title":"miR-30e-5p as predictor of generalization in ocular myasthenia gravis.","volume":"6","author":"Sabre","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205464","article-title":"MicroRNA and mRNA expression associated with ectopic germinal centers in thymus of myasthenia gravis.","volume":"13","author":"Sengupta","year":"2018","journal-title":"PLoS One"},{"key":"B69","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.","volume":"123","author":"Shen","year":"2013","journal-title":"J. Clin. Invest."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.12659\/MSM.893458","article-title":"miR-15b is downregulated in myasthenia gravis patients and directly regulates the expression of interleukin-15 (IL-15) in experimental myasthenia gravis mice.","volume":"21","author":"Shi","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"B71","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician.","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577080","article-title":"Myasthenia gravis: state of the art and new therapeutic strategies.","volume":"337","author":"Souto","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Antititin antibody in early- and late-onset myasthenia gravis.","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"B74","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1749-6632.2012.06773.x","article-title":"Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.","volume":"1274","author":"Tuzun","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12681","article-title":"Common gamma chain cytokines promote regulatory T cell development and survival at the CD4(+) CD8(+) stage in the human thymus.","volume":"88","author":"Vanhanen","year":"2018","journal-title":"Scand. J. Immunol."},{"key":"B76","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis.","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s10072-016-2500-6","article-title":"MicroRNA-338 and microRNA-21 co-transfection for the treatment of rat sciatic nerve injury.","volume":"37","author":"Wang","year":"2016","journal-title":"Neurol. Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s11481-013-9498-9","article-title":"Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response.","volume":"8","author":"Wang","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/cei.12265","article-title":"Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis.","volume":"176","author":"Wang","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1139\/gen-2018-0110","article-title":"An integrated analysis of mRNA and miRNA in skeletal muscle from myostatin-edited Meishan pigs.","volume":"62","author":"Xie","year":"2019","journal-title":"Genome"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1468-1331.2009.02729.x","article-title":"Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis.","volume":"16","author":"Yeh","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1007\/s10753-017-0589-2","article-title":"Immature exosomes derived from MicroRNA-146a overexpressing dendritic cells act as antigen-specific therapy for myasthenia gravis.","volume":"40","author":"Yin","year":"2017","journal-title":"Inflammation"},{"key":"B83","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10238-015-0358-1","article-title":"Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis.","volume":"16","author":"Zhang","year":"2016","journal-title":"Clin. Exp. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s10072-015-2149-6","article-title":"Treatment with recombinant tissue plasminogen activator alters the microRNA expression profiles in mouse brain after acute ischemic stroke.","volume":"36","author":"Zhao","year":"2015","journal-title":"Neurol. Sci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/eji.200939914","article-title":"Ectopic GC in the thymus of myasthenia gravis patients show characteristics of normal GC.","volume":"40","author":"Zuckerman","year":"2010","journal-title":"Eur. J. Immunol."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnins.2020.00507\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T05:21:37Z","timestamp":1590038497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnins.2020.00507\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":85,"alternative-id":["10.3389\/fnins.2020.00507"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2020.00507","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"article-number":"507"}}